{"transactions":[{"id":4636247,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-06T20:42:08.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":8680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5863480,"source":{"system":"sec-edgar","filing":"0001480212-26-000010","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1770121/000148021226000010/primarydocument.xml","form_type":"4"}},{"id":713594,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-07T20:31:18.000Z","date":"2026-07-06","kind":"grant","planned":false,"acquired":true,"shares":6297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5854800,"source":{"system":"sec-edgar","filing":"0001480212-26-000008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000148021226000008/primarydocument.xml","form_type":"4"}},{"id":747841,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T20:34:54.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":90000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001480212-26-000006","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000148021226000006/primarydocument.xml","form_type":"4"}},{"id":812493,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-08T20:16:24.000Z","date":"2026-04-06","kind":"grant","planned":false,"acquired":true,"shares":7763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5848503,"source":{"system":"sec-edgar","filing":"0001480212-26-000004","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000148021226000004/primarydocument.xml","form_type":"4"}},{"id":946631,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:18:55.000Z","date":"2026-01-05","kind":"grant","planned":false,"acquired":true,"shares":6157,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5840740,"source":{"system":"sec-edgar","filing":"0001480212-26-000002","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000148021226000002/primarydocument.xml","form_type":"4"}},{"id":1022136,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T21:21:43.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":5628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5834583,"source":{"system":"sec-edgar","filing":"0001480212-25-000006","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000148021225000006/primarydocument.xml","form_type":"4"}},{"id":1090578,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-08T20:17:31.000Z","date":"2025-07-07","kind":"grant","planned":false,"acquired":true,"shares":7842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5828955,"source":{"system":"sec-edgar","filing":"0001562180-25-005349","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218025005349/primarydocument.xml","form_type":"4"}},{"id":1117831,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:40:10.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":80000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-25-004645","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218025004645/primarydocument.xml","form_type":"4"}},{"id":1175426,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:22:32.000Z","date":"2025-04-07","kind":"grant","planned":false,"acquired":true,"shares":16339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5821113,"source":{"system":"sec-edgar","filing":"0001562180-25-003066","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218025003066/primarydocument.xml","form_type":"4"}},{"id":1307948,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-07T21:26:29.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":14285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5804774,"source":{"system":"sec-edgar","filing":"0001562180-25-000238","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218025000238/primarydocument.xml","form_type":"4"}},{"id":1388603,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-09T20:11:06.000Z","date":"2024-10-07","kind":"grant","planned":false,"acquired":true,"shares":5938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5790489,"source":{"system":"sec-edgar","filing":"0001562180-24-007283","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218024007283/primarydocument.xml","form_type":"4"}},{"id":1454544,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-15T20:09:15.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a clerical error with regard to the number of option shares acquired."}],"balance_after":65000,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-24-005716","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218024005716/primarydocument.xml","form_type":"4/A","original_submission_date":"2024-06-07"}},{"id":1458287,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-07-08T20:32:21.000Z","date":"2024-07-05","kind":"grant","planned":false,"acquired":true,"shares":4911,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5784551,"source":{"system":"sec-edgar","filing":"0001562180-24-005643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218024005643/primarydocument.xml","form_type":"4"}},{"id":1477394,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2024-06-17T20:17:47.000Z","date":"2024-06-14","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date."}],"balance_after":130000,"derivative":{"exercise_price":2.36,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001415889-24-017183","document":"form4-06172024_080643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588924017183/form4-06172024_080643.xml","form_type":"4"}},{"id":1486689,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:21:38.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":54278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2025 and (ii) immediately prior to the 2025 annual meeting of stockholders of Sana Biotechnology, Inc. (\"Sana\"), provided that the reporting person provides continuous service to Sana through such date."}],"balance_after":54278,"derivative":{"exercise_price":7.36,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":54278},"source":{"system":"sec-edgar","filing":"0001562180-24-004839","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218024004839/primarydocument.xml","form_type":"4"}},{"id":1545548,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T20:51:08.000Z","date":"2024-04-05","kind":"grant","planned":false,"acquired":true,"shares":2774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5779640,"source":{"system":"sec-edgar","filing":"0001562180-24-003354","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218024003354/primarydocument.xml","form_type":"4"}},{"id":1570449,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-19T22:18:16.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":750,"price":147.48,"value":110610.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors."}],"balance_after":24976.307,"source":{"system":"sec-edgar","filing":"0001127602-24-010679","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760224010679/form4.xml","form_type":"4"}},{"id":1570448,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-03-19T22:18:16.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":1678,"price":147.48,"value":247471.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"169.013 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock."}],"balance_after":24226.307,"source":{"system":"sec-edgar","filing":"0001127602-24-010679","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760224010679/form4.xml","form_type":"4"}},{"id":1684159,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-08T22:38:26.000Z","date":"2024-01-05","kind":"grant","planned":false,"acquired":true,"shares":4901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5776866,"source":{"system":"sec-edgar","filing":"0001562180-24-000342","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218024000342/primarydocument.xml","form_type":"4"}},{"id":1763461,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-06T20:20:43.000Z","date":"2023-10-05","kind":"grant","planned":false,"acquired":true,"shares":6925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units for which the Reporting Person has elected to defer settlement until January 1, 2024 pursuant to Sana Biotechnology, Inc.'s Non-Employee Director Compensation Program."}],"balance_after":5771965,"source":{"system":"sec-edgar","filing":"0001562180-23-007236","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218023007236/primarydocument.xml","form_type":"4"}},{"id":1784761,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-09-08T20:20:59.000Z","date":"2023-09-08","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":55000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-09-07","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-23-048779","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123048779/doc4.xml","form_type":"4"}},{"id":1833784,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-06T20:21:24.000Z","date":"2023-07-05","kind":"grant","planned":false,"acquired":true,"shares":4152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units for which the Reporting Person has elected to defer settlement until January 1, 2024 pursuant to Sana Biotechnology, Inc.'s Non-Employee Director Compensation Program."}],"balance_after":5765040,"source":{"system":"sec-edgar","filing":"0001562180-23-005765","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218023005765/primarydocument.xml","form_type":"4"}},{"id":1849692,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2023-06-20T20:40:16.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":3.19,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-23-038433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123038433/doc4.xml","form_type":"4"}},{"id":1860436,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T20:30:50.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 8, 2024 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 8, 2023."}],"balance_after":65000,"derivative":{"exercise_price":6.7,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-23-005025","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218023005025/primarydocument.xml","form_type":"4"}},{"id":1923691,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-06T20:45:17.000Z","date":"2023-04-05","kind":"grant","planned":false,"acquired":true,"shares":7716,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units for which the Reporting Person has elected to defer settlement until January 1, 2024 pursuant to Sana Biotechnology, Inc.'s Non-Employee Director Compensation Program."}],"balance_after":5760888,"source":{"system":"sec-edgar","filing":"0001562180-23-003474","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218023003474/primarydocument.xml","form_type":"4"}},{"id":1945053,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T01:38:35.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":741,"price":136.82,"value":101383.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors."}],"balance_after":22379.294,"source":{"system":"sec-edgar","filing":"0000899243-23-009220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000089924323009220/doc4.xml","form_type":"4"}},{"id":1945052,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T01:38:35.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":1658,"price":136.82,"value":226847.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"127.761 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock."}],"balance_after":21638.294,"source":{"system":"sec-edgar","filing":"0000899243-23-009220","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000089924323009220/doc4.xml","form_type":"4"}},{"id":2060346,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-06T21:17:18.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":6702,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5753172,"source":{"system":"sec-edgar","filing":"0001562180-23-000267","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218023000267/primarydocument.xml","form_type":"4"}},{"id":2141262,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-06T20:05:34.000Z","date":"2022-10-05","kind":"grant","acquired":true,"shares":4012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5746470,"source":{"system":"sec-edgar","filing":"0001562180-22-007109","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218022007109/primarydocument.xml","form_type":"4"}},{"id":2162386,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-09-09T20:05:52.000Z","date":"2022-09-08","kind":"exercise","acquired":false,"shares":145380,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":24230,"derivative":{"exercise_price":0.1,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":145380},"source":{"system":"sec-edgar","filing":"0001209191-22-049299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122049299/doc4.xml","form_type":"4"}},{"id":2162385,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-09T20:05:52.000Z","date":"2022-09-08","kind":"exercise","acquired":true,"shares":145380,"price":0.1,"value":14538.0,"ownership":{"direct":true},"balance_after":4685614,"source":{"system":"sec-edgar","filing":"0001209191-22-049299","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122049299/doc4.xml","form_type":"4"}},{"id":2210720,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-07T20:32:11.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":3328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5742458,"source":{"system":"sec-edgar","filing":"0001562180-22-005623","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218022005623/primarydocument.xml","form_type":"4"}},{"id":2236200,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-10T20:11:35.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":5.31,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-22-035846","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122035846/doc4.xml","form_type":"4"}},{"id":2239035,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-08T22:33:13.000Z","date":"2022-06-06","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 6, 2023 and (ii) immediately prior to Sana Biotechnology, Inc.'s next annual meeting of stockholders following June 6, 2022."}],"balance_after":65000,"derivative":{"exercise_price":4.95,"expiration_date":"2032-06-05","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001562180-22-004940","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218022004940/primarydocument.xml","form_type":"4"}},{"id":2302501,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-06T21:55:41.000Z","date":"2022-04-05","kind":"grant","acquired":true,"shares":2880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":5739130,"source":{"system":"sec-edgar","filing":"0001562180-22-003313","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000156218022003313/primarydocument.xml","form_type":"4"}},{"id":2323499,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-03-21T21:03:44.000Z","date":"2022-03-17","kind":"grant","acquired":true,"shares":797,"price":136.82,"value":109045.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors."}],"balance_after":19852.533,"source":{"system":"sec-edgar","filing":"0001127602-22-010045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760222010045/form4.xml","form_type":"4"}},{"id":2323498,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-03-21T21:03:44.000Z","date":"2022-03-17","kind":"grant","acquired":true,"shares":1785,"price":136.82,"value":244223.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"94.6360 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock."}],"balance_after":19055.533,"source":{"system":"sec-edgar","filing":"0001127602-22-010045","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760222010045/form4.xml","form_type":"4"}},{"id":2372310,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-02-25T21:05:49.000Z","date":"2022-02-23","kind":"exercise","acquired":false,"shares":993428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the option shares vested on September 20, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase."}],"balance_after":169610,"derivative":{"exercise_price":0.1,"expiration_date":"2028-11-05","underlying":"Common Stock","underlying_shares":993428},"source":{"system":"sec-edgar","filing":"0001209191-22-013118","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122013118/doc4.xml","form_type":"4"}},{"id":2372309,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-25T21:05:49.000Z","date":"2022-02-23","kind":"exercise","acquired":true,"shares":993428,"price":0.1,"value":99342.8,"ownership":{"direct":true},"balance_after":4540234,"source":{"system":"sec-edgar","filing":"0001209191-22-013118","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122013118/doc4.xml","form_type":"4"}},{"id":2657487,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-06-23T21:35:22.000Z","date":"2021-06-21","kind":"exercise","acquired":false,"shares":546806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":546806},"source":{"system":"sec-edgar","filing":"0001209191-21-042796","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919121042796/doc4.xml","form_type":"4"}},{"id":2657486,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-23T21:35:22.000Z","date":"2021-06-21","kind":"exercise","acquired":true,"shares":546806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date."}],"balance_after":3546806,"source":{"system":"sec-edgar","filing":"0001209191-21-042796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919121042796/doc4.xml","form_type":"4"}},{"id":2776682,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-22T19:14:55.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":822,"price":121.593,"value":99949.446,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors."}],"balance_after":17175.897,"source":{"system":"sec-edgar","filing":"0001127602-21-011652","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760221011652/form4.xml","form_type":"4"}},{"id":2776681,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-22T19:14:55.000Z","date":"2021-03-18","kind":"grant","acquired":true,"shares":1850,"price":121.593,"value":224947.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"48.199 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan."}],"balance_after":16353.897,"source":{"system":"sec-edgar","filing":"0001127602-21-011652","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760221011652/form4.xml","form_type":"4"}},{"id":2850040,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-19T00:02:26.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":23591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in full on February 3, 2022."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This Form 4/A is being filed to correct a calculation error in regards to the number of option shares acquired."}],"balance_after":23591,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":23591},"source":{"system":"sec-edgar","filing":"0000899243-21-007197","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000089924321007197/doc4a.xml","form_type":"4/A","original_submission_date":"2021-02-05"}},{"id":2869121,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-02-11T00:00:33.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":156250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The expiration date is not relevant to the conversion of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":156250},"source":{"system":"sec-edgar","filing":"0000899243-21-005749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000089924321005749/doc4.xml","form_type":"4"}},{"id":2869120,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2021-02-11T00:00:33.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The expiration date is not relevant to the conversion of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0000899243-21-005749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000089924321005749/doc4.xml","form_type":"4"}},{"id":2869119,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2021-02-11T00:00:33.000Z","date":"2021-02-08","kind":"exercise","acquired":false,"shares":1075000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The expiration date is not relevant to the conversion of these securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1075000},"source":{"system":"sec-edgar","filing":"0000899243-21-005749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000089924321005749/doc4.xml","form_type":"4"}},{"id":2869118,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-11T00:00:33.000Z","date":"2021-02-08","kind":"exercise","acquired":true,"shares":2031250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering."}],"balance_after":5736250,"source":{"system":"sec-edgar","filing":"0000899243-21-005749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000089924321005749/doc4.xml","form_type":"4"}},{"id":2876612,"issuer":{"id":4870,"kind":"organization","name":"Sana Biotechnology, Inc.","symbol":"SANA"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T22:21:31.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on February 3, 2022."}],"balance_after":14000,"derivative":{"exercise_price":25,"expiration_date":"2031-02-02","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-21-005082","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000089924321005082/doc4.xml","form_type":"4"}},{"id":3068235,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-08-05T22:30:41.000Z","date":"2020-08-03","kind":"grant","acquired":true,"shares":177,"price":93.91,"value":16622.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"51.097 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan."}],"balance_after":14455.698,"source":{"system":"sec-edgar","filing":"0001127602-20-022974","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760220022974/form4.xml","form_type":"4"}},{"id":3172639,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-04-21T23:32:57.000Z","date":"2020-04-17","kind":"grant","acquired":true,"shares":1027,"price":73.009,"value":74980.243,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors."}],"balance_after":14227.601,"source":{"system":"sec-edgar","filing":"0001127602-20-014242","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760220014242/form4.xml","form_type":"4"}},{"id":3172638,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-04-21T23:32:57.000Z","date":"2020-04-17","kind":"grant","acquired":true,"shares":3081,"price":73.009,"value":224940.729,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"87.391 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan."}],"balance_after":13200.601,"source":{"system":"sec-edgar","filing":"0001127602-20-014242","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760220014242/form4.xml","form_type":"4"}},{"id":3361966,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:30:19.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":4756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of   Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested.  The converted restricted stock units will be settled as promptly as practicable following the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested.  The converted restricted stock units will be settled as promptly as practicable following the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested.  The converted restricted stock units will be settled as promptly as practicable following the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4756},"source":{"system":"sec-edgar","filing":"0001415889-19-001362","document":"form4-11222019_071107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001362/form4-11222019_071107.xml","form_type":"4"}},{"id":3361965,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-11-22T07:30:19.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":1454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of   Celgene common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested.  The converted restricted stock units will be settled as promptly as practicable following the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested.  The converted restricted stock units will be settled as promptly as practicable following the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested.  The converted restricted stock units will be settled as promptly as practicable following the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1454},"source":{"system":"sec-edgar","filing":"0001415889-19-001362","document":"form4-11222019_071107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001362/form4-11222019_071107.xml","form_type":"4"}},{"id":3361964,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:30:19.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":13266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":77.38,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":13266},"source":{"system":"sec-edgar","filing":"0001415889-19-001362","document":"form4-11222019_071107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001362/form4-11222019_071107.xml","form_type":"4"}},{"id":3361963,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T07:30:19.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was fully exercisable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":91.01,"expiration_date":"2028-04-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-19-001362","document":"form4-11222019_071107.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001362/form4-11222019_071107.xml","form_type":"4"}},{"id":3361962,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-22T07:30:19.000Z","date":"2019-11-20","kind":"disposition_to_issuer","acquired":false,"shares":23088,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition in connection with the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 2, 2019, by and among Celgene Corporation (\"Celgene\"), Bristol-Myers Squibb Company (\"BMS\"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS (\"Merger Sub\"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the \"Effective Time\"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right (\"CVR\") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-19-001362","document":"form4-11222019_071107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919001362/form4-11222019_071107.xml","form_type":"4"}},{"id":3501343,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-06-05T16:05:54.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":4756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022.  Vested shares will be delivered to the reporting person promptly after the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022.  Vested shares will be delivered to the reporting person promptly after the vesting date."}],"balance_after":4756,"derivative":{"underlying":"Common Stock","underlying_shares":4756},"source":{"system":"sec-edgar","filing":"0001415889-19-000669","document":"form4-06052019_040641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588919000669/form4-06052019_040641.xml","form_type":"4"}},{"id":3582008,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-03-22T18:20:50.000Z","date":"2019-03-21","kind":"grant","acquired":true,"shares":627.435,"price":82,"value":51449.67,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest quarterly in 25% increments, with the first vesting on the date of grant."}],"balance_after":10032.21,"source":{"system":"sec-edgar","filing":"0001127602-19-012816","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760219012816/form4.xml","form_type":"4"}},{"id":3582007,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-03-22T18:20:50.000Z","date":"2019-03-21","kind":"grant","acquired":true,"shares":2823,"price":82,"value":231486.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"60.027 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan."}],"balance_after":9404.775,"source":{"system":"sec-edgar","filing":"0001127602-19-012816","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760219012816/form4.xml","form_type":"4"}},{"id":3893142,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-15T16:27:11.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":1454,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Company's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person as follows: 484 shares on June 13, 2023; 485 shares on June 13, 2024; and 485 shares on June 13, 2025 at the reporting person's election to defer receipt of such shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person as follows: 484 shares on June 13, 2023; 485 shares on June 13, 2024; and 485 shares on June 13, 2025 at the reporting person's election to defer receipt of such shares."}],"balance_after":1454,"derivative":{"underlying":"Common Stock","underlying_shares":1454},"source":{"system":"sec-edgar","filing":"0001415889-18-000943","document":"form4-06152018_010654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000943/form4-06152018_010654.xml","form_type":"4"}},{"id":3893141,"issuer":{"id":15781,"kind":"organization","name":"CELGENE CORP /DE/"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T16:27:11.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":13266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The option was issued pursuant to the Company's 2017 Stock Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next annual stockholder meeting."}],"balance_after":13266,"derivative":{"exercise_price":77.38,"expiration_date":"2028-06-13","underlying":"Common Stock","underlying_shares":13266},"source":{"system":"sec-edgar","filing":"0001415889-18-000943","document":"form4-06152018_010654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/816284/000141588918000943/form4-06152018_010654.xml","form_type":"4"}},{"id":3984207,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-03-23T22:27:09.000Z","date":"2018-03-22","kind":"grant","acquired":true,"shares":1438.063,"price":67.47,"value":97026.11061,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Shares of Agilent Technologies, Inc. common stock held in a deferral account pursuant to the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors that vest quarterly in 25% increments, with the first vesting on the date of grant."}],"balance_after":6521.748,"source":{"system":"sec-edgar","filing":"0001127602-18-012670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760218012670/form4.xml","form_type":"4"}},{"id":3984206,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-03-23T22:27:09.000Z","date":"2018-03-22","kind":"grant","acquired":true,"shares":2876,"price":67.47,"value":194043.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. The reporting person has elected to defer receipt of these shares of common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"8.865 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan."}],"balance_after":5083.685,"source":{"system":"sec-edgar","filing":"0001127602-18-012670","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760218012670/form4.xml","form_type":"4"}},{"id":4008212,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":205823,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":205823},"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008211,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":24.5,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008210,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":140000,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":48.06,"expiration_date":"2025-03-02","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008209,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":451756,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":451756},"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008208,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":35893,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F7","text":"Represents performance-based restricted stock awards (\"PSAs\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008207,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":66426,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":35893,"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008206,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":33133,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock of the Company underlying time-based restricted stock units (\"RSUs\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement)."}],"balance_after":102319,"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008205,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":48829,"price":87,"value":4248123.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents time-based restricted stock awards (\"RSAs\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, these RSAs (the remaining unvested portions of which were fully accelerated under the Merger Agreement) were cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00."}],"balance_after":135452,"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4008204,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-03-07T23:15:08.000Z","date":"2018-03-05","kind":"other","acquired":false,"shares":2263948,"price":87,"value":196963476.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (3) through (8) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes."}],"balance_after":184281,"source":{"system":"sec-edgar","filing":"0001209191-18-017800","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118017800/doc4.xml","form_type":"4"}},{"id":4068548,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-02-10T00:29:48.000Z","date":"2018-02-07","kind":"gift","acquired":false,"shares":116280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a bona fide gift of common stock; thus, there is no price associated with this transaction."}],"balance_after":2448229,"source":{"system":"sec-edgar","filing":"0001209191-18-009013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118009013/doc4.xml","form_type":"4"}},{"id":4068547,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-02-10T00:29:48.000Z","date":"2018-02-07","kind":"tax_withholding","acquired":false,"shares":4346,"price":85.49,"value":371539.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units."}],"balance_after":2564509,"source":{"system":"sec-edgar","filing":"0001209191-18-009013","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118009013/doc4.xml","form_type":"4"}},{"id":4079174,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-02-03T00:28:32.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":66426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018."}],"balance_after":2568855,"source":{"system":"sec-edgar","filing":"0001209191-18-007207","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118007207/doc4.xml","form_type":"4"}},{"id":4096156,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"exercise","acquired":false,"shares":245750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter."}],"balance_after":451756,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":245750},"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4096155,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":42457,"price":48.5648,"value":2061915.7136,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016, as amended March 14, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This transaction was executed in multiple trades at prices ranging from $48.13 to $48.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2502429,"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4096154,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":23003,"price":47.6925,"value":1097070.5775,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016, as amended March 14, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $47.13 to $48.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2544886,"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4096153,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":49082,"price":46.5247,"value":2283525.3254,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016, as amended March 14, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $46.13 to $47.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2567889,"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4096152,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":89888,"price":45.5321,"value":4092789.4048,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016, as amended March 14, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $45.13 to $46.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2616971,"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4096151,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":65820,"price":44.7163,"value":2943226.866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016, as amended March 14, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $44.13 to $45.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2706859,"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4096150,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2018-01-19T02:30:59.000Z","date":"2018-01-16","kind":"exercise","acquired":true,"shares":245750,"price":6.36,"value":1562970.0,"ownership":{"direct":true},"balance_after":2772679,"source":{"system":"sec-edgar","filing":"0001209191-18-004433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919118004433/doc4.xml","form_type":"4"}},{"id":4182448,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2017-10-21T00:25:29.000Z","date":"2017-10-20","kind":"grant","acquired":true,"shares":35893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards (\"RSAs\") granted pursuant to the 2014 Equity Incentive Plan. The RSAs will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date:\n\nUp to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the \"FDA\") of JCAR017 in any indication within certain designated timeframes (the \"JCAR017 Milestone\"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement.\n\nUp to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes."}],"balance_after":2526929,"source":{"system":"sec-edgar","filing":"0001209191-17-057693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919117057693/doc4.xml","form_type":"4"}},{"id":4255578,"issuer":{"id":3062,"kind":"organization","name":"AGILENT TECHNOLOGIES, INC.","symbol":"A"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-07-18T22:29:22.000Z","date":"2017-07-18","kind":"grant","acquired":true,"shares":2199,"price":61.21,"value":134600.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. Under the Agilent Technologies, Inc. 2005 Deferred Compensation Plan for Non-Employee Directors, the reporting person has elected to defer receipt of these shares of common stock."}],"balance_after":2199,"source":{"system":"sec-edgar","filing":"0001127602-17-023806","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1090872/000112760217023806/form4.xml","form_type":"4"}},{"id":4459527,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-10T00:33:27.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":205823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter."}],"balance_after":205823,"derivative":{"exercise_price":20.76,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":205823},"source":{"system":"sec-edgar","filing":"0001209191-17-009292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919117009292/doc4.xml","form_type":"4"}},{"id":4459526,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2017-02-10T00:33:27.000Z","date":"2017-02-07","kind":"grant","acquired":true,"shares":44177,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017."}],"balance_after":2491036,"source":{"system":"sec-edgar","filing":"0001209191-17-009292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919117009292/doc4.xml","form_type":"4"}},{"id":4592607,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-29T22:02:59.000Z","date":"2016-09-27","kind":"exercise","acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter."}],"balance_after":697506,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001209191-16-143182","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116143182/doc4.xml","form_type":"4"}},{"id":4592606,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-29T22:02:59.000Z","date":"2016-09-27","kind":"sale","acquired":false,"shares":44000,"price":33,"value":1452000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016."}],"balance_after":2446859,"source":{"system":"sec-edgar","filing":"0001209191-16-143182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116143182/doc4.xml","form_type":"4"}},{"id":4592605,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-29T22:02:59.000Z","date":"2016-09-27","kind":"exercise","acquired":true,"shares":44000,"price":6.36,"value":279840.0,"ownership":{"direct":true},"balance_after":2490859,"source":{"system":"sec-edgar","filing":"0001209191-16-143182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116143182/doc4.xml","form_type":"4"}},{"id":4597943,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-21","kind":"exercise","acquired":false,"shares":6057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter."}],"balance_after":741506,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":6057},"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597942,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-20","kind":"exercise","acquired":false,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter."}],"balance_after":747563,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597941,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-19","kind":"exercise","acquired":false,"shares":428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter."}],"balance_after":753863,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":428},"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597940,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-21","kind":"sale","acquired":false,"shares":77307,"price":30.3024,"value":2342587.6368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2014, as amended March 20, 2015, and pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016."}],"balance_after":2446859,"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597939,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-21","kind":"exercise","acquired":true,"shares":6057,"price":6.36,"value":38522.52,"ownership":{"direct":true},"balance_after":2524166,"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597938,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-20","kind":"sale","acquired":false,"shares":6300,"price":30.0005,"value":189003.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2014, as amended March 20, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":2518109,"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597937,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-20","kind":"exercise","acquired":true,"shares":6300,"price":6.36,"value":40068.0,"ownership":{"direct":true},"balance_after":2524409,"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597936,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-19","kind":"sale","acquired":false,"shares":428,"price":30,"value":12840.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2014, as amended March 20, 2015."}],"balance_after":2518109,"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4597935,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2016-09-21T23:34:26.000Z","date":"2016-09-19","kind":"exercise","acquired":true,"shares":428,"price":6.36,"value":2722.08,"ownership":{"direct":true},"balance_after":2518537,"source":{"system":"sec-edgar","filing":"0001209191-16-142344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116142344/doc4.xml","form_type":"4"}},{"id":4606760,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":31685,"kind":"person","name":"Bishop Hans Edgar","position":1,"cik":"0001480212","reported_name":"Bishop Hans Edgar","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-09-10T00:07:16.000Z","date":"2016-09-08","kind":"exercise","acquired":false,"shares":23042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option became vested and exercisable on October 9, 2014 and 1/48th of the shares subject to the option vested monthly thereafter."}],"balance_after":754291,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-08","underlying":"Common Stock","underlying_shares":23042},"source":{"system":"sec-edgar","filing":"0001209191-16-140851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1480212/000120919116140851/doc4.xml","form_type":"4"}}],"next_cursor":"2016-09-10T00:07:16.000000Z,4606760"}